Bioventus Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
Index to Consolidated Financial Statements
| Page | |
|---|---|
| Bioventus Inc. | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID Number 248) | 88 |
| Consolidated Statements of Operations and Comprehensive Income (Loss) | 89 |
| Consolidated Balance Sheets | 90 |
| Consolidated Statements of Changes in Stockholders’ Equity | 91 |
| Consolidated Statements of Cash Flows | 92 |
| Notes to the Consolidated Financial Statements | 93 |
| Note 1. Organization | 93 |
| Note 2. Significant Accounting Policies | 95 |
| Note 3. Balance Sheet Information | 104 |
| Note 4. Divestitures | 107 |
| Note 5. Financial Instruments | 107 |
| Note 6. Fair Value Measurements | 110 |
| Note 7. Equity-Based Compensation | 111 |
| Note 8. Stockholders’ Equity | 114 |
| Note 9. Earnings Per Share | 115 |
| Note 10. Restructuring Costs | 116 |
| Note 11. Income Taxes | 116 |
| Note 12. Commitments and Contingencies | 120 |
| Note 13. Revenue Recognition | 124 |
| Note 14. Segments | 125 |
| Note 15. Discontinued Operations | 127 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.